How Can We Improve the Solute and Fluid Transport Prescriptions in Hemodialysis to Improve Patient Outcomes?

Gotch, Frank A.; Kotanko, Peter; Levin, Nathan W.

doi:10.1159/000346283

Cited by 3 publications

(3 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following reports of centres employing long-term extended daytime HD demonstrating significantly improved five-and ten-year patient survival rates of 73% and 54% respectively (Charra et al 1992, Chazot & Jean 2008, the focus has switched to intensive dialysis regimens (Gotch et al 2013) Our local observational data (Singh et al 2013) concurs with findings from international registries that longer treatment time is associated with lower mortality risk (Tentori et al 2012). Consequently, the Frequent Haemodialysis Network (FHN) (Chertow et al 2010) were commissioned to review the relationships between daily short duration HD and daily long duration nocturnal HD in randomised controlled trials.…”

Section: B I O D a T Asupporting

confidence: 77%

Survey of Staff Opinions About Extended Haemodialysis Treatment Time and Service Implications

Singh

Procter

Power

et al. 2015

Journal of Renal Care

View full text Add to dashboard Cite

There is conflict between the understanding that extended TT is clinically beneficial and its prescription & delivery to patients. Enrolment to studies examining HD delivery strategies may be influenced by service provision and staff attitudes. In centre HD has been designed to maximise patient throughput and we may need to consider more flexible settings in which to deliver longer treatment time: Home HD maybe a solution.

show abstract

Section: B I O D a T Asupporting

confidence: 77%

Survey of Staff Opinions About Extended Haemodialysis Treatment Time and Service Implications

Singh

Procter

Power

et al. 2015

Journal of Renal Care

View full text Add to dashboard Cite

show abstract

“…A previously conducted study also associated HD with significant net increases in removal of several uremic toxins including β2‐MG, homocysteine (Hcy) and Scr as well as a net decrease in circulating inflammatory markers such as interleukin‐6 (IL‐6), demonstrating the significant therapeutic effects of HD in toxin elimination and inflammation, thus supporting its clinical value in ESRD patients . In addition, HD consists of conventional low‐flux HD and convective therapies, which could remove excess fluid and metabolic wastes from patients and maintain the normal physiological levels of electrolyte and acid‐base balance …”

Section: Discussionmentioning

confidence: 90%

CD62P and P10 as predictive markers for assessing the efficacy of hemodialysis in treating end‐stage renal disease

Wang

et al. 2018

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background CD62P is a platelet α‐granule membrane protein, and P10 is a platelet membrane glycoprotein thrombospondin. To better understand the effects of hemodialysis (HD), we have conducted this study to investigate CD62P and P10 in assessing the efficacy of HD in treating patients with end‐stage renal disease (ESRD). Methods The case group consisted of 111 patients suffering ESRD treated with regular HD and the control group enrolled 117 healthy subjects. Before and after HD treatment, a series of parameters were observed, based on which, CD62P and P10 levels were detected in the patients in two groups before and after HD therapy. The correlation analysis analyzed the correlations of CD62P and P10 markers with serum creatinine (Scr), blood urea nitrogen (BUN), and subjective score; and logistic regression analysis was performed to reveal factors affecting the efficacy of HD. Results BUN, Scr, serum phosphorus, intact parathyroid hormone (iPTH), fibrinogen, and β2‐microglobulin (β2‐MG) decreased while hemoglobin, albumin, and activated partial thromboplastin time increased in the patients suffering ESRD; patients presented with improvements in subjective symptoms and an increase in dry weight. CD62P and P10 levels were lower in post‐treatment patients. CD62P and P10 positively correlated with Scr, BUN and subjective score; post‐treatment CD62P and P10 levels, BUN, hemoglobin, albumin, triglyceride, iPTH, β2‐MG, and fibrinogen were correlated with the efficacy of HD. Conclusion CD62P and P10 might be correlated to the efficacy of HD in treating ESRD, in turn providing predictive markers for assessing the ability of HD in treating ESRD.

show abstract

“…Currently, four hours per session is recommended in a thrice-weekly dialysis schedule [13]. As this advice is mainly based on nonrandomized studies, which are prone to confounding, a treatment time of four hours is rather arbitrary, especially since patient characteristics, such as body size and residual kidney function, are not taken into consideration [28,29]. …”

Section: Discussionmentioning

confidence: 99%

Treatment Time or Convection Volume in HDF: What Drives the Reduced Mortality Risk?

Zuijdewijn

Nubé²,

Wee³

et al. 2015

Blood Purif

View full text Add to dashboard Cite

Background/Aims: Treatment time is associated with survival in hemodialysis (HD) patients and with convection volume in hemodiafiltration (HDF) patients. High-volume HDF is associated with improved survival. Therefore, we investigated whether this survival benefit is explained by treatment time. Methods: Participants were subdivided into four groups: HD and tertiles of convection volume in HDF. Three Cox regression models were fitted to calculate hazard ratios (HRs) for mortality of HDF subgroups versus HD: (1) crude, (2) adjusted for confounders, (3) model 2 plus mean treatment time. As the only difference between the latter models is treatment time, any change in HRs is due to this variable. Results: 114/700 analyzed individuals were treated with high-volume HDF. HRs of high-volume HDF are 0.61, 0.62 and 0.64 in the three models, respectively (p values <0.05). Confidence intervals of models 2 and 3 overlap. Conclusion: The survival benefit of high-volume HDF over HD is independent of treatment time.

show abstract

How Can We Improve the Solute and Fluid Transport Prescriptions in Hemodialysis to Improve Patient Outcomes?

Cited by 3 publications

References 42 publications

Survey of Staff Opinions About Extended Haemodialysis Treatment Time and Service Implications

Survey of Staff Opinions About Extended Haemodialysis Treatment Time and Service Implications

CD62P and P10 as predictive markers for assessing the efficacy of hemodialysis in treating end‐stage renal disease

Treatment Time or Convection Volume in HDF: What Drives the Reduced Mortality Risk?

Contact Info

Product

Resources

About